News and Blog / News

Partnership enables local oncology genomic testing to broaden patient access to expedited, personalized care where it matters most - close to home

Comprehensive Genetic Profiling Supplements Germline and Companion Diagnostic Results to Provide Holistic View for Oncologists and Patients

Additional Illumina assays to be combined with the PierianDx platform to reduce time, cost, and complexity of genomic reporting 

Mark McDonough named as Chief Executive Officer (CEO) and member of the Board of Directors of PierianDx 

Multiple targeted assays from Pillar Biosciences to be combined with the PierianDx platform to reduce time, cost, and complexity of clinical genomic testing

Collaboration will create integrated clinical interpretation and reporting solution

Intermountain Healthcare joins PierianDx’s partner network to accelerate precision medicine

Funding led by ATW Partners and SJF Ventures with follow-on Investment from Health Catalyst Capital, RTI International, and Inova Health Systems

Comprehensive pan-cancer tumor profiling assays to be combined with clinical informatics platform with the potential to reduce time, cost, and complexity of clinical genomic analysis

PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that the Department of Anatomical Pathology PathWest Laboratory Medicine will use the company’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for clinical genomic analytics, classification, interpretation and reporting.

As posted on BusinessWire

MAY 24, 2018 -- ST. LOUIS -- PierianDx, the leader in clinical genomics solutions, announced today that it has appointed Michael L. Sanderson as Chief Executive Officer and Director of the Board. In his new role, Sanderson will execute on the company’s strategy to integrate PierianDx’s unique value proposition for molecular labs into the broader precision medicine and healthcare delivery markets.